<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01342042</url>
  </required_header>
  <id_info>
    <org_study_id>CSPC/PRO-rE4/IIa-04</org_study_id>
    <nct_id>NCT01342042</nct_id>
  </id_info>
  <brief_title>The Safety,Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese Type 2 Diabetes Mellitus</brief_title>
  <acronym>SPPS</acronym>
  <official_title>The Safety, Preliminary Pharmacodynamics and Pharmacokinetics Study of rExenatide-4 in Chinese T2DM</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Peking University People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Peking University First Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research is randomized, controlled trial. 36 Chinese subjects with Type 2 Diabetes
      Mellitus will take part in the trial.

      Subjects will randomly enter into one of three groups, administration daily twice, the period
      of is 84 days treatment. Subjects should be in hospital for pharmacokinetic studies in 1 d~
      8d, 30 d (if necessary)and 84 d, during 9 d ~ 83 d outpatient follow-up.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>March 2011</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in HbA1c</measure>
    <time_frame>12 Weeks</time_frame>
    <description>To observe and compare the differences in pharmacokinetic parameters with the reatment of rE-4, adding metformin to rE-4 and exenatide, To compare treatment arms in terms of change from baseline to endpoint in HbA1c</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in GA</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in fasting serum glucose</measure>
    <time_frame>12 Weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in postprandial blood glucose 2-hour</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To compare treatment arms in terms of change from baseline to endpoint in body weight</measure>
    <time_frame>12 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">36</enrollment>
  <condition>Type 2 Diabetes</condition>
  <arm_group>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>exenatide-4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>rExenatide-4</intervention_name>
    <description>This protein of 39 amino acids has been isolated from the venom of the lizard Heloderma suspectum (Gila monster) (Eng et al, 1992). A mammalian homolog does not seem to exist (Pohl and Wank, 1998). Exendin-4 shares 53 % identity at the amino acid level with that of the mammalian hormone GLP-1 [glucagon-like peptide-1] (Chen and Drucker, 1997). Exendin-4 is encoded within a prohormone that is distinct from the prohormone encoding glucagon. Using transgenic mice expressing exendin-4, Adatia et al (2002) have shown that mammalian cells process the lizard prohormone in endocrine and nonendocrine cell types in vitro and in murine tissues in vivo.</description>
    <arm_group_label>Metformin</arm_group_label>
    <arm_group_label>exenatide-4</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. 18 ~ 75 years with T2DM in China;

          2. HbA1c of 7% to 13%;

          3. negative pregnancy test in females, all subjects have no family planning during the
             test and after the end within 3 months.

        Exclusion Criteria:

          1. HBsAg, HCV, HIV and syphilis test was positive;

          2. any time FBG &lt;6.1 or&gt; 14.0 mmol / L in the morning;

          3. Renal function: eGFR &lt;60 mL / min ;

          4. TG&gt; 5mmol / L;

          5. Pancreatitis, cholecystitis, gallstones and other gastrointestinal diseases;

          6. Ischemic heart disease, heart failure, stroke or peripheral vascular disease;

          7. Pregnancy and breast-feeding women;

          8. Patients requiring insulin treatment;

          9. Have medical history of hypoglycemia;

         10. Have a clear history of allergic patients;

         11. Patients addicted to alcohol and tobacco.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Cui Yi min, MD</last_name>
    <role>Study Director</role>
    <affiliation>Peking University First Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cui Yi Min, MD</last_name>
    <phone>86-10-88325988</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Peking</city>
        <state>Beijing</state>
        <zip>010</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cui Yi Min, MD</last_name>
      <phone>86-10-88325988</phone>
    </contact>
    <investigator>
      <last_name>Cui Yi Min, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 23, 2011</study_first_submitted>
  <study_first_submitted_qc>April 25, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 26, 2011</study_first_posted>
  <last_update_submitted>April 25, 2011</last_update_submitted>
  <last_update_submitted_qc>April 25, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 26, 2011</last_update_posted>
  <responsible_party>
    <name_title>CSPC ZhongQi Pharmaceutical Technology Co., Ltd.</name_title>
    <organization>CSPC</organization>
  </responsible_party>
  <keyword>diabetes</keyword>
  <keyword>rRE-4</keyword>
  <keyword>exenatide</keyword>
  <keyword>metformin</keyword>
  <keyword>CSPC ZhongQi</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Exenatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

